GE Healthcare Life Sciences & ASLS unite to advance 3D biofabrication
Category: #health  By Pankaj Singh  Date: 2019-12-10
  • share
  • Twitter
  • Facebook
  • LinkedIn

GE Healthcare Life Sciences & ASLS unite to advance 3D biofabrication

 

  • The alliance is aimed at personalizing regenerative tissue manufacturing processes
  • Vascularized printed cells are set to pave the way for more complex biological structures including soft tissue, organ replacements and bone
  • GE Healthcare Life Sciences & ASLS will develop an integrated and accurate method of cellular imaging & biofabrication to print cells

GE Healthcare division, GE Healthcare Life Sciences has reportedly struck up an R&D and distribution partnership with Advanced Solutions Life Sciences. This collaboration will allow the companies to open up new avenues for regenerative tissue manufacturing.

The partnership will bring together GE’s IN Cell Analyzer and ASLS’s BioAssemblyBot® technologies in order to integrate cellular-level assessments into the 3D bioprinting process for generating human tissue models.

A primary drawback of bioprinted tissues is that they are smaller in size and tend to die at a fast pace, stemming from a lack of ability to generate small blood vessels, which make up the body’s supply network. ASLS’s proprietary technology Angiomics® is challenging this by allowing bioprinted microvessels to assemble themselves into functional capillary beds which supply the required oxygen, hormones and nutrients to the 3D tissue model and eliminate waste. This alliance will provide tissue engineers and life scientists to design, develop and image vascularized 3D tissues in a swift single process.

GE Healthcare Life Sciences’ Genomics & Cellular Research GM Emmanuel Abate has apparently claimed that the combination of the flexible and precise BioAssemblyBot® and the IN Cell Analyzer 6500 HS confocal screening platform’s high image quality and speed will realize the scope of automating the high content screening in 3D tissue models.

ASLS CEO & President Michael Golway also expressed his view on the matter stating that the cumulative power of these two technologies would achieve new heights in speed, quality and accuracy by leveraging 3D biofabrication and assay designs.

The printing of multi-material 3D models in microwell plates will enable scientists to transition from conventional 2D plastic monocultures to 3D cytotoxicity and discovery models which will present a more accurate reflection of disease and native biology.
 

Source Credit: https://finance.yahoo.com/news/ge-healthcare-life-sciences-pairs-124500933.html



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

US buys all of the global supply of Gilead’s COVID-19 drug remdesivir
US buys all of the global supply of Gilead’s COVID-19 drug remdesivir
By Pankaj Singh

While top-notch companies are racing to develop a vaccine for COVID-19, it looks like the United States has secured almost all of the world’s supply of interim drug remdesivir to treat patients with COVID-19.

...

Potential COVID-19 vaccine by Bharat Biotech to enter clinical trials
Potential COVID-19 vaccine by Bharat Biotech to enter clinical trials
By Pankaj Singh

Bharat Biotech International, a leading Indian biotechnology company, has reportedly announced that its potential coronavirus vaccine, Covaxin, has received Drug Controller General of India (DCGI) approval to start hum...

Seattle Genetics reveals positive data from tisotumab vedotin trial
Seattle Genetics reveals positive data from tisotumab vedotin trial
By Pankaj Singh

Seattle Genetics, Inc., a renowned biotechnology firm that focuses on developing antibody-based cancer treatments, has recently revealed positive topline data from its Phase 2 clinical trial (innovaTV 204) assessing ti...